Why Am I Not Hungry Anymore?
Updated: Oct 1
One of the first changes many patients notice after starting treatment is a significant reduction in appetite. For some, this can feel surprising. If you've spent years feeling hungry between meals, suddenly feeling less interested in food can take some getting used to.
Is This Normal?
Yes. Reduced appetite is one of the intended effects of Wegovy and Mounjaro.
These medications work by helping your body better regulate hunger and fullness signals. Many patients report:
Feeling full sooner
Eating smaller portions
Less interest in snacking
Fewer cravings throughout the day
Does This Mean I Should Stop Eating?
No. Even if your appetite is reduced, your body still needs adequate nutrition. This is especially important for:
Protein intake
Hydration
Vitamins and minerals
Preserving muscle mass during weight loss
Many patients find it helpful to focus on regular, balanced meals rather than waiting until they feel hungry.
Will My Appetite Stay This Low Forever?
Appetite suppression varies between individuals. Some patients experience significant reductions in hunger, while others notice more subtle changes. Your appetite may also fluctuate over time as your body adapts to treatment.
What If I'm Barely Eating?
Occasionally, appetite suppression can become excessive. Please contact the Medara clinical team if you are:
Struggling to eat enough
Losing weight too rapidly
Feeling weak or dizzy
Having difficulty staying hydrated
We may be able to provide guidance or adjust your treatment plan.
The Medara Takeaway
A reduced appetite is one of the ways GLP-1 medications help support weight loss.
The goal is not to stop eating, but to make it easier to eat appropriate portions while maintaining good nutrition and long-term health.
References:
Blundell J, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017. PubMed
Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week randomized controlled trial. 2026. PubMed
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
Written and clinically reviewed by: Dr Saran Seker, MBBS (Aus), Chief Medical Officer
Last reviewed: September 2026
Comments